MARKET

SPRB

SPRB

SPRUCE BIOSCIENCES, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.93
-0.06
-0.25%
Opening 12:38 10/30 EDT
OPEN
22.00
PREV CLOSE
21.98
HIGH
22.43
LOW
21.25
VOLUME
38.35K
TURNOVER
--
52 WEEK HIGH
22.52
52 WEEK LOW
15.12
MARKET CAP
466.20M
P/E (TTM)
-28.1378
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 29)
Benzinga · 4h ago
The Daily Biotech Pulse: Sanofi-GlaxoSmithKline To Supply 200M Doses To COVID-19 Vaccine Alliance, Gilead Earnings, Biodesix Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 27)
Benzinga · 2d ago
The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 26)
Benzinga · 3d ago
Spruce Biosciences reports 21.5% stake in Spruce Biosciences
In a regulatory filing, Novo Holdings disclosed a 21.5% (~4.98M shares) stake in Spruce Biosciences (SPRB), based upon 23,163,593 shares of Spruce’s common stock outstanding post the IPO.Tiba Aynechi, Ph.D.,
Seekingalpha · 10/19 10:00
Novo Holdings reports 21.5% stake in Spruce Biosciences
In a regulatory filing, Novo Holdings disclosed a 21.5% (~4.98M shares) stake in Spruce Biosciences (SPRB), based upon 23,163,593 common shares outstanding post the IPO.Novo Holdings A/S acquired an aggregate
Seekingalpha · 10/19 10:00
Airbus Is Struggling. And a Contract to Build a Mars Spacecraft Cant Lift the Earthbound Gloom.
The big European aircraft maker continues to be battered as its airline customers cut their orders and trade disputes swirl. Even a trip to Mars couldn’t help the stock.
Barrons.com · 10/17 00:38
The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Treatment, Can Fite Issues Psoriasis Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 14)
Benzinga · 10/15 12:03
Spruce Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares
Spruce Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Business Wire · 10/14 21:05
More
Forecast
EPSBVPSCFPS
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SPRB. Analyze the recent business situations of SPRUCE BIOSCIENCES, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.81%
Pharmaceuticals & Medical Research
-1.06%
Key Executives
Chairman/Director
Michael Grey
Chief Executive Officer/Director/Primary Contact
Richard King
Vice President
Chris Barnes
Other
Michael Huang
Director
Niall O Donnell
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SPRB
Spruce Biosciences, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for endocrine disorders. The Company's development product candidate, tildacerfont, is a non-steroidal therapy that offers disease control for patients suffering from congenital adrenal hyperplasia (CAH). Tildacerfont is a non-steroidal, oral antagonist of the corticotropin-releasing hormone receptor 1 (CRF1) receptor, which is the receptor for corticotropin-releasing factor (CRF). By blocking the CRF1 receptor, tildacerfont enables to address the uncontrolled cortisol feedback regulatory pathway in CAH and reduce the production of adrenocorticotropic hormone (ACTH) in the pituitary, limiting the amount of androgen produced downstream from the adrenal gland. Tildacerfont also enables treating physicians to lower the supraphysiologic glucocorticoid doses given to CAH patients to near physiologic levels.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Spruce Biosciences Inc stock information, including NASDAQ:SPRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPRB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SPRB stock methods without spending real money on the virtual paper trading platform.